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Abstract
Background: Africa is facing a rapidly growing chronic non-communicable disease burden whilst
at the same time experiencing continual high rates of infectious disease. It is well known that some
infections increase the risk of certain chronic diseases and the converse. With an increasing dual
burden of disease in Sub Saharan Africa the associations between diseases and our understanding
of them will become of increased public health importance.
Aims: In this review we explore the relationships reported between tuberculosis and diabetes
mellitus, human immunodeficiency virus, its treatment and metabolic risk. We aimed to address the
important issues surrounding these associations within a Sub Saharan African setting and to
describe the impact of globalization upon them.
Findings: Diabetes has been associated with a 3-fold incident risk of tuberculosis and it is
hypothesised that tuberculosis may also increase the risk of developing diabetes. During co-morbid
presentation of tuberculosis and diabetes both tuberculosis and diabetes outcomes are reported
to worsen. Antiretroviral therapy for HIV has been associated with an increased risk of developing
metabolic syndrome and HIV has been linked with an increased risk of developing both diabetes
and cardiovascular disease. Globalization is clearly related to an increased risk of diabetes and
cardiovascular disease. It may be exerting other negative and positive impacts upon infectious and
chronic non-communicable disease associations but at present reporting upon these is sparse.
Conclusion: The impact of these co-morbidities in Sub Saharan Africa is likely to be large. An
increasing prevalence of diabetes may hinder efforts at tuberculosis control, increasing the number
of susceptible individuals in populations where tuberculosis is endemic, and making successful
treatment harder. Roll out of anti-retroviral treatment coverage within Sub Saharan Africa is an
essential response to the HIV epidemic however it is likely to lead to a growing number of
individuals suffering adverse metabolic consequences. One of the impacts of globalization is to
create environments that increase both diabetes and cardiovascular risk but further work is needed
to elucidate other potential impacts. Research is also needed to develop effective approaches to
reducing the frequency and health impact of the co-morbidities described here.
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In Sub-Saharan Africa (SSA) infectious diseases still cause
the majority of mortality (69% of deaths). Chronic non-
communicable diseases such as cardiovascular disease,
diabetes mellitus (DM), chronic respiratory disease and
cancers, contribute around a quarter of deaths[1]. This
picture is changing as SSA undergoes an epidemiological
transition with a rapidly increasing burden of, and associ-
ated mortality from, chronic non-communicable diseases.
It has long been recognised that infective agents may pre-
dispose to, or trigger, some chronic non-communicable
diseases with examples including infective contributions
to cervical, liver and stomach cancers, and possible infec-
tive triggers for some types of diabetes[2,3]. In addition it
is becoming clear that two of the most common infectious
diseases in Africa, tuberculosis (TB) and human immuno-
deficiency virus (HIV)/acquired immune deficiency syn-
drome (AIDS), may also be closely related to chronic non-
communicable diseases [4-13]. Diabetes predisposes to
tuberculosis with some evidence that TB may also predis-
pose to diabetes[10,14-16]. Antiretroviral therapy for HIV
may increase the risk of metabolic syndrome (the cluster-
ing of abdominal obesity, hyperglycaemia, dyslipidaemia
and hypertension) and thus predispose to type 2 diabetes
and cardiovascular disease[6,7,9,11,17,18].
In this article we discuss the evidence on the relationships
between TB and DM, and the possible mechanisms
through which this link may be caused, we then discuss
the link between antiretroviral therapy (ART), metabolic
syndrome (MS) and cardiovascular disease (CVD). We
also address the potential public health importance of
these relationships within SSA and describe the possible
impact of globalization upon these associations. In order
to review these areas we have considered matters from
biological, medical and social science perspectives where
needed.
This article is based on detailed literature searches under-
taken by the authors for articles published since 1950.
Searches were undertaken in MEDLINE and EMBASE, plus
screening of reference lists in identified articles. Poten-
tially relevant reports, bulletins and guidelines were also
screened, including ones from the United Nations (UN),
World Health Organization (WHO), International Diabe-
tes Federation (IDF) and UK Department of Health
(DoH).
Diabetes Mellitus (DM) and Tuberculosis (TB)
Diabetes increases the risk of TB
An association between DM and TB has long been cited.
In around 1000 A.D. Avicenna noted that 'phthisis', tuber-
culosis, often complicated diabetes[19]. In the UK, in the
1950's, some joint TB and diabetes clinics were set up to
treat individuals with concomitant disease which were
reported to improve outcomes[20,21]. However, until
recent years there was a lack of good evidence on the
strength and nature of the association between TB and
DM. At present recognition of the association between
diabetes and TB is low. The link goes unmentioned in
many national and global TB control strategies even
though it is plausible that diabetes is a major threat to
effective TB control and the attainment of the TB Millen-
nium Development Goals as well as other national and
global targets [22-26].
Studies have shown an increased risk of TB infection in
individuals with both type 1 and type 2 diabetes although
measures of the strength of the association do
vary[10,12,27-31]. Recently a meta-analysis of 3 studies
carried out by Murray and Jeon showed that having diabe-
tes was associated with a relative risk (RR) of 3.11 for con-
tracting TB[10]. Stevenson et al carried out a systematic
review of the subject finding that diabetes has been esti-
mated to increase the risk of TB infection from 1.5 in one
study up to 7.8 times in an other[12]. Stevenson et al also
looked at the reported effects of age, gender and ethnicity
upon the strength of the association between TB and DM.
Reporting that gender did not seem to affect the RR for TB
amongst individuals with DM, but that age did. The RR
seems to be highest at younger ages and shows a decline
as age increases, although this finding is not replicated in
all studies, some show no association between the RR of
TB amongst individuals with DM and of older age[12].
The increased risk of contracting TB for DM patients has
been demonstrated in many different study populations.
One study reports a difference in the association between
TB and DM in different ethnic groups[28]. The study
reports that DM is not a risk factor for TB in 'Black Hispan-
ics' but is amongst 'White Americans' and 'Hispanics'. The
cause of this finding is unclear; the investigators state that
it may be due to unidentified HIV infection among 'black'
controls which could attenuate any association found
between diabetes and tuberculosis[28]. In order to gain a
better awareness of the effect of ethnicity upon the
strength of the RR of individuals with DM for contracting
TB further investigation is needed.
Estimates of the population attributable risk (PAR) for TB
from diabetes illustrate the potential importance of this
relationship. PAR is dependent upon the prevalence of the
risk factor (diabetes) and the strength of its relationship to
the outcome (TB) and provides, given certain assump-
tions, an estimate of the proportion of the outcome that is
directly caused by the risk factor. Stevenson et al estimated
that diabetes accounts for approximately 14.8% of inci-
dent Pulmonary Tuberculosis (PTB) in India, and a
slightly higher amount of TB infection has been found to
be attributable to DM (25%) in a Mexican setting[16,30].Page 2 of 9
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Although the majority of studies identify and discuss the
presence of diabetes as a risk factor for TB, the relationship
between DM and TB is posited to be bidirectional. Early
studies by Engelbach et al and Nichols et al reported that
not only could having diabetes increase an individuals
likelihood of developing TB but that having TB could lead
to the presentation of diabetes[32,33]. Work carried out
by Karachunskii et al showed that individuals with TB can
develop changes in carbohydrate metabolism such as
insulin deficiency and persistent hyperglycaemia[34].
Impaired glucose tolerance (IGT) and increased rates of
DM have been found amongst TB patients in an African
setting. A Tanzanian study found TB patients to have
increased rates of IGT and a Nigerian study found an
increased level of IGT and DM amongst TB patients. These
results have been interpreted as an indication that TB can
cause DM[14,15]. However, given the cross sectional
rather than longitudinal design of these studies, their
results are also compatible with undetected DM and IGT
being present prior to the onset of TB. It is well known
that in most populations a large proportion of those with
DM or intermediate hyperglycaemia are undiagnosed and
only detected upon blood glucose testing.
Although uncertainty remains around whether TB is a risk
factor for DM it is clear that tuberculosis, as with other
infections, complicates diabetes management and that
some of the TB treatment regimes, including Isoniazid,
have hyperglycaemic effects[35].
Reported mechanisms causing the association
DM is known to impair immune function[36,37]. Specif-
ically DM hinders cell mediated immunity and has been
associated with low levels of leucocytes, polymorphonu-
clear neutrophils (PMNs) and a decreased T-helper1
cytokine response to TB [36,38,39] (PMNs produce
cytokines and carry out phagocytosis[40]). T-helper 1
(Th1) type cytokines are vital in the control and inhibi-
tion of TB, for example, Interferon Gamma (IFN-γ) is
important for combating microbial infection and both
IFN-γ and Tumor Necrosis Factor alpha (TNFα, another
Th1 cytokine) attack TB via the activation of macrophages
[38-41]. Activated macrophages release reactive oxygen
species (ROS) and free radicals such as Nitric Oxide which
are essential for infection control, including TB infec-
tion[38,40]. Not only are macrophages the primary site of
TB infection but they also instigate the main immune
response to TB[12,41]. Macrophage function is inhibited
in individuals with diabetes, the production of ROS, and
phagocytic and chemotactic abilities are impaired. All of
which are important for TB clearance[38,39,42].
Depressed immunity in DM patients would plausibly
cause a higher risk of developing TB. Pulmonary microan-
giopathy occurs as a complication of DM and could par-
tially explain the increased risk of lung infection for
individuals with DM as well as the altered presentation of
TB during co-morbidity[43]. Deficiencies in vitamins A, C
and D are linked both with an increased risk of DM and
TB. It has been hypothesised that there is a pathway upon
which they act that dictates susceptibility to both diseases
[44-47].
As afore mentioned some TB medications such as Isoni-
azid have been shown to have hyperglycaemic effects giv-
ing plausible mechanisms as to why glucose control is
impaired in TB patients[35]. Inflammation caused by IL6
and TNFα whilst modulating a response to TB infection
could cause an increase in insulin resistance thus decreas-
ing insulin production causing an increase in blood glu-
cose[48]. Although no singular mechanism has been
identified as the cause of the associations between TB and
DM many plausible causal pathways have been suggested.
Effect on health outcomes when TB and DM are 
concomitant
An associated deterioration of both conditions occurs dur-
ing co-morbidity with TB and DM. It is known that diabe-
tes makes TB management more difficult and that chronic
stimulation of the inflammatory system by TB may affect
diabetes management and outcomes. In a study carried
out in Mumbai, a higher mortality rate for tuberculosis
when complicated with diabetes was seen. This increased
mortality rate has been found elsewhere[49,50]. Co-pres-
entation of TB and DM was associated with increased dia-
betes related complications in a recent study and poorer
blood glucose control[13,28]. Tight blood glucose control
is thought to reduce the risk of TB infection in an individ-
ual with DM[13,28].
Co-presentation with TB and DM has also been associated
with more severe TB symptoms and clinical presentation;
increased lung cavitations, and longer periods of smear
positivity[51,52]. In co-morbid patients the involvement
of the lower lung field is more common, Sosman and
Steidl found multilobular cavitary TB was more common
in people with diabetes[52]. However, there are relatively
few studies that look at the lung pathology of co-infected
DM-TB patients, data is sparse and sometimes contradic-
tory, and as such it should be considered cautiously. In
Nijmegen researchers monitored TB patients both with
and without diabetes while they received treatment, they
found that co-morbid individuals were more likely to
have positive sputum results after six months of TB treat-
ment, 22.2% compared with only 9.5% of the non-com-
plicated TB cases. This suggests TB bacterial clearance
takes a longer time in DM patients. Animal models have
shown that hyperglycaemia causes higher TB bacterial
loads than you would see in animals with normal blood
glucose, this implies that infectivity is greater duringPage 3 of 9
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and could relate to the increased clearance times seen[53].
Data upon the effect co-morbidity has on the likelihood
of the TB infection being multi-drug resistant is inconsist-
ent. In a study carried out on the Texas border population
it was found that multi-drug resistant TB (MDR-TB) was
associated with DM with an Odds Ratio of 2.1[42]. Other
studies have shown no increased association between DM
and MDR-TB. Incompletion of TB treatment is a major
cause of primary drug resistance. DM patients are thought
to have impaired gastrointestinal drug absorption due to
gastroparesis which may affect treatments. A study by Nij-
land et al reported that Rifampicin is not absorbed as
effectively in TB-DM patients, this could again be due to
poor gastrointestinal uptake, or due to differences in
metabolism, excretion and body weight[54]. This poor
intake of anti-TB drugs by DM patients could be a possible
mechanism that leads to the development of drug resist-
ance.
HIV, Metabolic Syndrome, and Heart Disease
Metabolic Syndrome
Metabolic abnormalities such as; glucose intolerance,
Insulin resistance, abdominal adiposity high BP, and low
HDL cholesterol and raised triglycerides tend to cluster,
and it is the presence of these clustered abnormalities
which are referred to as Metabolic Syndrome (MS). There
is no universally accepted definition for MS but the 3 most
often used are those as set out by the World Health Organ-
isation (WHO), International Diabetes Federation (IDF)
and National Cholesterol Education Program Adult Treat-
ment Panel 3 (NCEPATPIII) [55-57]. Probably the most
relevant to be used within an African setting due to its
clinical accessibility is that of the IDF which requires for
the diagnosis of MS central obesity, plus two of the fol-
lowing four additional factors: raised triglycerides,
reduced high density lipoprotein cholesterol, raised blood
pressure, or raised fasting plasma glucose[57].
Anti Retroviral Treatment
Anti-retroviral treatment (ART) is the main management
regimen for HIV/AIDS, it consists of a number of drugs
that suppress viral replication and decrease viral load[58].
HAART (highly active antiretroviral therapy) is the gold
standard for treatment where three or more drugs are
combined in order to prevent the development of drug
resistance. There are currently five classes of ART drug cat-
egorised on the basis by which they suppress HIV infec-
tion; Protease inhibitors (PIs), Nucleoside or nucleotide
reverse transcriptase inhibitors (NRTI), Non nucleoside
reverse transcriptase inhibitors (NNRTI), fusion inhibi-
tors and integrase inhibitors[58]. Widespread use of ART
in high-income countries has profoundly changed the
outlook for HIV+ individuals, reducing both morbidity
and mortality. Once someone starts ART they will remain
upon it for life.
HIV and ART causing Metabolic Syndrome
The range of potential adverse consequences of ART is
wide and includes gastro-intestinal disturbance, hepato-
toxicity, pancreatitis, peripheral neuropathy, mitochon-
drial toxicity and anaemia[59]. Risk associations between
HIV, its treatment, and various features of MS have been
reported. It is during the treatment of HIV with ART that
metabolic syndrome can be induced. The mechanism for
this is unknown but it is thought to either be due to the
infectious, inflammatory, process of HIV itself, a form of
drug induced toxicity or perhaps through indirect effects.
Two classes of ART, nucleoside reverse transcriptase inhib-
itors (NRTIs) and protease inhibitors (PIs) have been
associated with inducing MS[18,60,61]. HIV treatment
with protease inhibitors has not only been associated with
hyperglycaemia, but the development of insulin resist-
ance (a feature of MS and precursor to DM), increased lev-
els of cholesterol and triglycerides, lipodystrophy, and the
onset or complication of diabetes[18,60].
We will discuss further the association seen between HIV
and three major components of MS, dyslipidemia, lipod-
ystrophy and insulin resistance. Although these three fea-
tures of MS are clearly inter-related the nature of these
relationships are not yet fully understood, so, in order to
describe their association with MS as noted in the litera-
ture we will do so separately.
Risk of HIV Lipodystrophy (HIV-LD) in HIV+ patients
HIV Lipodystrophy (HIV-LD) is seen in long term survi-
vors of HIV infection, most of whom are receiving ART.
HIV-LD is a complex syndrome thought to occur due to
the secondary effects of HIV infection, direct drug-induced
toxicities and, or, the indirect effects of changes in body
composition on lipid metabolism[62]. The syndrome
consists of both metabolic abnormalities (hyperlipidae-
mia and IR) and body fat redistribution (central adiposity
and peripheral fat wasting). Central adiposity is manifest
by the accumulation of visceral fat in the intra-abdominal
space (abdominal obesity), dorsocervical spine (buffalo
hump) and the breasts. Peripheral wasting describes loss
of subcutaneous adipose tissue (lipoatrophy) in the
limbs, face and buttocks in a generalised fashion. Both
central adiposity and peripheral wasting can occur
together but the underlying processes typically take place
independently so that most often one feature is present
alone[8]. The risk of central adiposity and peripheral
wasting is greatly increased in HIV+ patients on ART. In the
Lancet, in 1997, the first report on body fat redistribution
in an HIV+ person associated with PI-treatment was pub-
lished[60]. The following year, 1998, Carr et al designed a
cross-sectional study to characterise the syndrome thatPage 4 of 9
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determine if it was seen in association with all PI use or
only in HIV patients using PIs. Healthy individuals, PI
naïve HIV+ patients and HIV+ patients on PIs, were com-
pared[18]. It was already known that Protease Inhibitors
cause certain metabolic abnormalities such as hypergly-
caemia but, this publication was the first to report that
HIV patients on PIs had an increased risk of developing a
syndrome of lipodystrophy with hyperlipidaemia and IR.
It is now accepted that PI and other ART use in HIV+ indi-
viduals are associated with fat redistribution. Studies on
nevirapine [63] (an NNRTI) and stavudine, and lamivu-
dine [59,64] (NRTIs) have all shown an association
between usage and changes in fat deposition. All ART tri-
als that have included objective body shape evaluation
have consistently found an increased risk of abdominal
fat in HIV patients regardless of which ART is used. How-
ever it is unknown which ARTs cause the most severe accu-
mulation of visceral fat[65].
Risk of Dyslipidemia in HIV+ patients
Dyslipidaemia is characterised by hypertriglyceridaemia,
hypercholesterolaemia and low serum high density lipo-
protein (HDL) cholesterol, features of defective lipopro-
tein metabolism[6]. Although abnormal lipid profiles are
reported in HIV+ individuals before the onset of ART,
hypertriglyceridaemia becomes both more prevalent and
severe during treatment[66]. Sullivan et al in 1998
reported a case in which serum triglycerides markedly
increased after 5 months of treatment with ritonavir (a
PI). In the same patient there was also an increase in cho-
lesterol, both concentrations returned to baseline 5 weeks
after discontinuing ritonavir showing the association to
be treatment rather than infection led[67].
Hypertriglyceridaemia and hypercholesterolaemia have
been reported to occur with long term usage of drugs from
the three main classes of ART, however, the association
seems most common place with the use of PIs. Chen et al
report prevalence of dyslipidaemia (defined as hypertrig-
lyceridaemia, hypercholesterolaemia and low HDL) in
HIV+ individuals being treated with HAART as 70-80%
and state that it can be associated with all available PIs[6].
It has also been reported that severe hypertriglyceridaemia
associated with PI therapy can lead to acute pancreati-
tis[67].
Risk of Insulin Resistance in HIV+ patients
It is also known that HIV+ people are at increased risk of
IR due to the pro-inflammatory process of HIV, the direct
effects of ARTs and also, indirect effects as consequences
of ART (for example body fat distribution changes). The
pathogenesis of ART-induced IR has been the focus of
much discussion. Evidence suggests that body fat distribu-
tion changes cause increased fat deposition in muscle
which is accompanied by impaired insulin sensitivity[17].
It has been shown that ART regimens impair glucose tol-
erance in one of two ways; induction of peripheral IR in
skeletal muscle and adipose tissue and impairment of
pancreatic beta cells to compensate[17]. It has also been
reported that PIs bind to and block the insulin sensitive
glucose transporter GLUT4[68]. Less is known about the
mechanisms involved in the NRTIs effect on insulin sensi-
tivity[11]. It has been well documented that IR is related
to abdominal obesity, hypertriglyceridaemia and is asso-
ciated with type 2 DM[18] There is much controversy as to
whether it is changes in body composition that reflect
underlying metabolic changes or vice versa[69]. In a
recently published study in which ART-naïve patients
were randomised to receive either an NRTI-regimen or an
NRTI-sparing regimen, glucose and insulin were assessed
before and approximately three months after initiation of
therapy. The researchers reported that there was a reduc-
tion in peripheral insulin sensitivity without significant
changes in body fat distribution in the NRTI group but not
the NRTI-sparing group[70]. These findings indicate the
changes are not mediated by alteration in body composi-
tion but that the risk is associated with NRTI usage.
Risk of Heart Disease in HIV+ patients
Magula and Mayosi (2003) looked at cardiac involvement
in HIV patients and showed that abnormalities are com-
moner in HIV patients. Approximately half of hospitalised
HIV patients and a high number of out-patients were
found to develop cardiac abnormalities[71]. The DAD
study (Data Collection on Adverse Events of Anti-HIV
Drugs) assessed the risk of Myocardial Infarction (MI) in
HIV patients by measuring the incidence of MI in terms of
duration of HAART. The relative risk of an MI for an HIV
patient on HAART was shown to be raised and to increase
over time[7]. In another study cardiovascular disease risk
was found to be significantly higher in HIV patients with
MS in comparison to HIV patients with only abnormal
body fat redistribution. This shows that MS increases the
risk of MI more severely than body fat changes alone.
Based on the Framingham criteria [72] the researchers
report median percentage of cardiovascular disease risk at
ten years for those with the MS and those without to be 10
and 5 respectively. It is not known how the traditional car-
diovascular risk factors (e.g. smoking) modulate risk in
the HIV population[66].
Importance of these associations in a Sub-
Saharan African setting and the impact of 
globalization upon them
Importance of both associations within Sub Saharan Africa
Although much research is needed before we fully under-
stand the biological pathways and effect on disease rates
of the associations between the chronic and infectious dis-
eases discussed in this paper it is clear that they couldPage 5 of 9
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Saharan Africa. In 2004 the WHO estimated there were
8.9 million new cases of tuberculosis, of which only half
were reported to public-health authorities and, or,
WHO[73]. The WHO African region has the highest esti-
mated incident TB rate (356 per 100, 000 population per
year) [73]. A large proportion of the increase in incident
tuberculosis seen in Africa is attributable to the spread of
HIV. In 2004 34% of newly diagnosed TB cases in Africa
were estimated to be infected with HIV[73]. Diabetes Mel-
litus is a large cause of morbidity and mortality in Sub-
Saharan Africa. The IDF has estimated that the prevalence
of diabetes in SSA as a whole for 2006 was approximately
10.8 million, and they predict that this will rise by up to
80% by 2025 giving a prevalence of 18.7 million[74].
Could the large estimated rises in diabetes prevalence
impact upon the future prevalence of TB, due to the asso-
ciation between the two diseases, as the rises in HIV have
already been seen to?
As previously stated Stevenson et al estimated that Diabe-
tes accounts for approximately 14.8% of incident Pulmo-
nary Tuberculosis (PTB) in India, and a higher proportion
of TB infection has been found to be attributable to DM
(25%) in a Mexican setting[16,29,30]. These findings flag
the potential public health importance of the association
in Africa, although it must be noted that these estimates
were not carried out within high HIV settings. As the num-
bers of individuals with DM rise it is plausible that there
will be associated rises in the incidence of TB. The 2006
United Nations Joint Programme on HIV/AIDS
(UNAIDS) report estimated that 63% (24.7 million) of all
people infected with HIV worldwide resided in Sub-Saha-
ran Africa and that the majority of deaths globally
occurred here (72%, 2.8 million). All Southern African
countries with the exception of Angola have an estimated
adult HIV prevalence above 10%. In Botswana, Lesotho,
Swaziland, and Zimbabwe, the estimated adult HIV prev-
alence exceeds 20%[75]. Effective treatment of HIV infec-
tion with antiretroviral therapy (ART) is now available
even in countries with limited resources and in Africa the
number of individuals receiving treatment has been
greatly increased by the 3' by 5' campaign[75]. The large
increase that has occurred in the number of people on
ART has meant the number of people living with AIDS as
a chronic condition has massively increased.
The WHO and UNAIDS 3' by 5' initiative, aimed to pro-
vide treatment to 3 million people in low and middle
income countries by 2005. By December 2005, 18 coun-
tries had met their 3' by 5' target and 1.3 million individ-
uals were receiving ART. In Sub-Saharan Africa, the
number of people receiving HIV treatment increased more
than eight-fold to 810,000 from 100,000. Despite these
increases in ART, only 20% of those in need of treatment
were receiving it by December 2005[75]. The G8 nations
and the UN national assembly agreed to working with
WHO and UNAIDS to continue developing an essential
package of HIV prevention, treatment and care with the
aim of moving as close as possible to universal access to
treatment by 2010. The treatment of HIV with ARTs is a
huge and greatly needed advance decreasing morbidity
and mortality from HIV substantially but it has some
unintended consequences that require either preventive
efforts or appropriate treatment. If the goal of universal
ART treatment within SSA is met then a substantial rise in
metabolic syndrome, diabetes and heart disease may be
seen. More research is needed to know how important this
relationship will be globally and within SSA.
The impact of globalization upon both associations within 
Sub-Saharan Africa and beyond
Globalization, which can be defined as a process in which
regions are becoming increasingly interconnected via the
growing movement of people, goods, capital and ideas
has both positive and negative impacts on health[76].
One of the major processes indicative of globalization
currently ongoing in SSA is urbanisation, resulting from a
combination of natural population increase, reclassifica-
tion of areas formerly considered rural, and rural to urban
migration[77]. It is estimated that by 2020 the total urban
population in SSA will double so that 487 million indi-
viduals will be living in urban areas. Growth of the urban
populations within Sub Saharan African countries is
occurring presently at an average rate of 4.5% per
year[78]. Urbanisation in SSA, as in other less developed
parts of the world, is strongly associated with increased
levels of obesity, diabetes and cardiovascular disease[79].
In urban SSA obesity levels now equal those of the
west[80]. Lower levels of physical activity [81] and an
increasing calorie rich diet are key drivers of these
increased rates. The production of processed foods has
high profit margins and transnational food corporations
are amongst the largest sources of foreign direct invest-
ment in many countries of Sub Saharan Africa[82].
Indeed, it has been appreciated for many years that the
global availability and marketing of cheap vegetable oils
and fats is leading to increasing fat consumption in less
developed countries[83]. Obesity is the major risk factor
for Type 2 diabetes, which accounts for over 90% of all
diabetes[74], and rural-urban comparisons of diabetes in
SSA find 2 to 5 fold higher prevalence in urban
areas[81,84,85]. As an increase in diabetes prevalence
occurs alongside rapid urbanisation, it is reasonable given
the evidence reviewed here to suggest that this will make
TB control more difficult, and may even lead to a rise in
TB incidence. It is expected that numbers of individuals
affected by the co-morbidities of diabetes and TB will rise.
There are at least two million people who were born in
Sub Saharan Africa now living in North America or West-Page 6 of 9
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risk for TB and HIV to countries with a lower risk of these
conditions, meaning that they tend to be disproportion-
ately represented in their host countries amongst those
with TB and HIV. For example, according to the UK
Health Protection Agency, there were over 1500 new cases
of TB in the UK amongst people born in Africa in 2007,
which is an annual rate of more than 300 per 100,000
compared to less than 10 per 100,000 in the white UK
born population. In addition, people of African origin liv-
ing in the UK, and other richer countries, tend to be at
higher risk of diabetes, 2 to 4 fold higher, than the major-
ity white population[74]. It is therefore highly plausible,
but currently unknown, that international migrants from
Africa to richer parts of the world are at much greater risk
of the adverse combination of TB and diabetes. The poten-
tial importance of the relationships in international
migrants, moving from Africa to richer parts of the world,
is poorly researched and requires further attention.
Labour migration patterns in Africa are considered one of
the underlying determinants of the spread and distribu-
tion of HIV infection[87], which in turn is also linked to
the spread of TB infection. Economic globalization is
identified as one of the drivers of labour migration within
Africa, both within and between countries, and particu-
larly from rural to urban areas[88]. Thus an interaction is
occurring between globalization, the risk of HIV infection
and exposure to "obesogenic" urban environments. It is
only with wider availability of ART that this combination
becomes of public health importance giving a further
increased risk to HIV positive people on ARTs of develop-
ing metabolic syndrome, diabetes and cardiovascular dis-
ease. Even with the afore mentioned side effects ART is the
most essential response to the HIV/AIDs epidemic but the
potential health effects of its prolonged use need to be
addressed. Positive impacts of globalization are also seen.
As the world becomes increasingly interconnected it has
become easier to implement treatment in areas where dis-
ease is endemic and globalization, as represented through
the activities of international organisations such as the
United Nations/WHO, has played a large role in the
increased access individuals within SSA now have to ART.
Reduction in prices of ARTs for use within SSA by interna-
tional drug corporations and the pledges from private
donors have also contributed to this increased accessibil-
ity.
Conclusion
SSA is currently seeing a very large change in the major
health problems it faces. The link between chronic and
infectious diseases becomes more important as the epide-
miological transition in SSA progresses against a backdrop
of globalization. In this review we reported upon the asso-
ciations seen between two examples of chronic and infec-
tious disease.
The literature reports a clear association between DM and
TB and also discusses the possibility of this link being bi-
directional. Although the underlying mechanisms for the
association are not yet definite many possible pathways of
action have been reported. The link between TB and DM
will pose a serious threat to public health in SSA as DM
prevalence rises. There are also published studies report-
ing an association between HIV, its treatment and many
various features of metabolic syndrome. Although associ-
ations between HIV, its treatment using ART and HIV-LD,
insulin resistance, dyslipidemia and heart disease are now
accepted as occurring in western environments the mech-
anisms through which these occur are still under debate.
More research is needed in low income countries in order
to find the extent to which these issues will be a problem
in SSA.
An awareness of the problems that occur due to the asso-
ciations seen between chronic and infectious disease
should allow us to deal with them more efficiently. More
research however is needed upon the mechanisms of
action for these risk associations in order for effective pre-
vention or treatment of them to occur and more research
needs to be carried out before we truly understand how
globalization is impacting upon the associations.
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